[go: up one dir, main page]

ATE160818T1 - Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit - Google Patents

Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit

Info

Publication number
ATE160818T1
ATE160818T1 AT91910915T AT91910915T ATE160818T1 AT E160818 T1 ATE160818 T1 AT E160818T1 AT 91910915 T AT91910915 T AT 91910915T AT 91910915 T AT91910915 T AT 91910915T AT E160818 T1 ATE160818 T1 AT E160818T1
Authority
AT
Austria
Prior art keywords
compositions
methods
biological activity
identifying molecules
molecules
Prior art date
Application number
AT91910915T
Other languages
English (en)
Inventor
James J Devlin
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE160818T1 publication Critical patent/ATE160818T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91910915T 1990-06-01 1991-05-13 Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit ATE160818T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53318090A 1990-06-01 1990-06-01

Publications (1)

Publication Number Publication Date
ATE160818T1 true ATE160818T1 (de) 1997-12-15

Family

ID=24124831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910915T ATE160818T1 (de) 1990-06-01 1991-05-13 Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit

Country Status (10)

Country Link
EP (1) EP0600866B1 (de)
JP (1) JPH05507700A (de)
AT (1) ATE160818T1 (de)
AU (2) AU8081491A (de)
CA (1) CA2084307A1 (de)
DE (1) DE69128362T2 (de)
DK (1) DK0600866T3 (de)
ES (1) ES2109945T3 (de)
GR (1) GR3025596T3 (de)
WO (1) WO1991018980A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
EP0575410B1 (de) * 1991-03-07 1999-05-19 BRADBURY, Andrew Raymon Morton Auswahl spezifischer proteine durch ein biologisches verfahren
EP0580737B1 (de) * 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993007169A1 (en) * 1991-10-04 1993-04-15 Chiron Corporation Peptide inhibitors of platelet adhesion
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
AU685753B2 (en) * 1992-09-04 1998-01-29 Scripps Research Institute, The Phagemids coexpressing a surface receptor and a surface heterologous protein
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
EP0700522A1 (de) * 1993-05-28 1996-03-13 Chiron Corporation Verfahren zur auswahl von biologisch aktiven peptidsequenzen
IT1261693B (it) * 1993-06-01 1996-05-29 Angeletti P Ist Richerche Bio Metodologia per la produzione di fagi filamentosi che espongono sulla superficie del capside peptidi capaci di legare la biotina, e fagi filamentosi e peptidi cosi' ottenibili.
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE69526665T2 (de) * 1994-09-21 2002-11-21 Cytogen Corp., Princeton Antigen bindende peptide (abtides) aus peptidbibliotheken
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
ATE360641T1 (de) 1996-06-14 2007-05-15 Meiji Dairies Corp Peptide aus t-zellepitopen
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU5077401A (en) 2000-02-08 2001-08-20 Sangamo Biosciences Inc Cells for drug discovery
US7129326B2 (en) 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
JP4966470B2 (ja) 2000-04-14 2012-07-04 ダニスコ・ユーエス・インコーポレーテッド 選択性標的化方法
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU2002312566A1 (en) 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
AU2003233489B2 (en) 2002-04-08 2008-10-02 Pioneer Hi-Bred International, Inc. Enhanced silk exsertion under stress
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
PT1576179E (pt) 2002-11-27 2010-12-21 Irm Llc Métodos e composições para a indução de apoptose em células cancerosas
WO2004067736A2 (en) 2003-01-28 2004-08-12 Cellectis Custom-made meganuclease and use thereof
US20060188512A1 (en) 2003-02-01 2006-08-24 Ted Yednock Active immunization to generate antibodies to solble a-beta
JP4820291B2 (ja) 2003-05-19 2011-11-24 エラン ファーマシューティカルズ，インコーポレイテッド レヴィー小体病におけるαシヌクレインの切断断片
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
SI1701968T1 (sl) 2003-12-17 2015-08-31 Wyeth Llc Imunogeni konjugati peptidnih nosilcev in postopek izdelave istih
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006135382A2 (en) 2004-08-04 2006-12-21 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
EP2357257B1 (de) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methoden und reagentien für die behandlung und die diagnose von altersbedingter makularer degeneration
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
PA8675801A1 (es) 2005-05-19 2006-12-07 Centocor Inc Anticuerpos anti-mcp-1, composiciones, metodos y usos
PL1896073T3 (pl) 2005-06-30 2013-08-30 Janssen Biotech Inc Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
AU2006276813A1 (en) 2005-07-01 2007-02-15 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of influenza
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
EP2368868A1 (de) 2005-10-28 2011-09-28 Praecis Pharmaceuticals Inc. Verfahren zur Identifikation von Verbindungen von Interesse mithilfe kodierter Bibliotheken
PT1971366E (pt) 2005-12-29 2014-11-06 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
CA2653628C (en) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
HUE028731T2 (en) 2007-02-23 2016-12-28 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic diseases
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
ES2614735T3 (es) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
BRPI0819743A2 (pt) 2007-11-20 2014-10-07 Pioneer Hi Bred Int Ácido nucléico isolado, cassete de expressão, célula hospedeira, planta transgênica, semente transgênica, método para modular a resposta de etileno em uma planta, proteína isolada
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
AU2008345022B2 (en) 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
KR101453141B1 (ko) 2008-08-18 2014-10-23 재단법인서울대학교산학협력재단 라이실 ｔＲＮＡ 합성효소의 세포내 수준을 조절하여 암 전이 또는 암 세포의 이동을 조절하는 방법
EA028304B1 (ru) 2008-10-31 2017-11-30 Сентокор Орто Байотек Инк. Способы конструирования библиотеки белкового каркаса на основе домена фибронектина типа iii (fn3)
EP2396011B1 (de) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
WO2010101818A1 (en) 2009-03-02 2010-09-10 Pioneer Hi-Bred International, Inc. Nac transcriptional activators involved in abiotic stress tolerance
WO2010148365A2 (en) 2009-06-19 2010-12-23 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona For And On Behalf Of Arizona State University Compound arrays for sample profiling
WO2011017492A2 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
SI2558577T1 (sl) 2010-04-16 2019-05-31 Nuevolution A/S Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
EP2714921A4 (de) 2011-05-26 2015-05-13 Univ Michigan Epigenetische corepressoren des gamma-globin-gens und verwendungsverfahren dafür
JP6166263B2 (ja) 2011-09-22 2017-07-19 メディシナル バイオコンバージェンス リサーチ センター ロイシンｔＲＮＡ合成酵素の新規用途（ＮｏｖｅｌｕｓｅｏｆｌｅｕｃｙｌｔＲＮＡｓｙｎｔｈｅｔａｓｅ）
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
CN103958668A (zh) 2011-09-23 2014-07-30 路易斯维尔大学研究基金会公司 用于扩充细胞及改善嫁接的方法和组合物
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN103906835A (zh) 2011-10-25 2014-07-02 先锋国际良种公司 改变植物细胞壁组成以改善生物燃料生产和青贮饲料可消化性的方法
BR112015023703A2 (pt) 2013-03-15 2017-07-18 Pioneer Hi Bred Int modulação de expressão de deaminase de acc
US9678080B2 (en) 2013-06-14 2017-06-13 Pacific Biosciences Of California, Inc. Bis-biotinylation tags
LT3712174T (lt) 2013-12-24 2022-05-25 Janssen Pharmaceutica Nv Anti vista antikūnai ir fragmentai
WO2016169894A1 (en) 2015-04-20 2016-10-27 F. Hoffmann-La Roche Ag Specific peptide binders to proteins identified via systemic discovery, maturation and extension process
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
JP6989927B2 (ja) 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
KR20240034883A (ko) 2016-03-29 2024-03-14 얀센 바이오테크 인코포레이티드 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US11747334B2 (en) 2016-06-20 2023-09-05 Cowper Sciences Inc. Methods for differential diagnosis of autoimmune diseases
WO2017223117A1 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
US20190227082A1 (en) 2016-07-06 2019-07-25 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
US20190177421A1 (en) 2016-07-15 2019-06-13 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
WO2018064436A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
EP3538893A4 (de) 2016-11-11 2020-09-23 Healthtell Inc. Verfahren zur identifizierung von biomarker-kandidaten
US11208474B2 (en) 2016-11-16 2021-12-28 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL23 specific antibody
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
CN117959418A (zh) 2017-03-13 2024-05-03 波赛达治疗公司 用于选择性消除和替换造血干细胞的组合物和方法
US20200150109A1 (en) 2017-05-05 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
US20210130845A1 (en) 2017-09-08 2021-05-06 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
EP3762015A4 (de) 2018-03-05 2022-04-27 Janssen Biotech, Inc. Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
EP3824295A4 (de) 2018-07-18 2022-04-27 Janssen Biotech, Inc. Prädiktoren mit verzögerter wirkung nach behandlung mit anti-il23-spezifischem antikörper
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
US20220042038A1 (en) 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CA3133383A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
BR112021018441A2 (pt) 2019-03-18 2023-02-28 Janssen Biotech Inc Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
EP3953485A4 (de) 2019-04-10 2023-05-17 University of Utah Research Foundation Htra1-modulation zur behandlung von amd
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
JP2022535534A (ja) 2019-06-03 2022-08-09 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
CA3162246A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
EP4135758A1 (de) 2020-04-14 2023-02-22 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung bei der behandlung von krebs
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP4367137A1 (de) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
KR20240095537A (ko) 2021-10-04 2024-06-25 포세이다 테라퓨틱스, 인크. 트랜스포존 조성물 및 이의 이용 방법
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
CN119698430A (zh) 2022-03-30 2025-03-25 詹森生物科技公司 用il-23特异性抗体治疗轻度至中度银屑病的方法
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713366A (en) * 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
ATE151110T1 (de) * 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods

Also Published As

Publication number Publication date
GR3025596T3 (en) 1998-03-31
DE69128362D1 (de) 1998-01-15
AU8081491A (en) 1991-12-31
ES2109945T3 (es) 1998-02-01
EP0600866B1 (de) 1997-12-03
EP0600866A1 (de) 1994-06-15
DK0600866T3 (da) 1998-03-09
AU699732B2 (en) 1998-12-10
DE69128362T2 (de) 1998-05-20
WO1991018980A1 (en) 1991-12-12
AU3310595A (en) 1996-02-22
JPH05507700A (ja) 1993-11-04
CA2084307A1 (en) 1991-12-02

Similar Documents

Publication Publication Date Title
ATE160818T1 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
DE68903482D1 (de) Zement, verfahren zur herstellung dieses zements und verfahren zur herstellung von produkten mit diesem zement.
DE68923319D1 (de) Fluorkohlenstoff- Membranen und Verfahren zur Herstellung von Fluorkohlenstoff-Membranen.
DE58908382D1 (de) Verfahren und Vorrichtung zur Herstellung von Borstenwaren.
DE68913977D1 (de) Polymerzusammensetzung und verfahren zur herstellung.
DE69201589D1 (de) Wachsumhüllte Partikel und Verfahren zur Herstellung derselben.
DE68912336D1 (de) Hydrophobe proteinmikroteilchen und verfahren zur herstellung.
DE69126762D1 (de) Biologisches Verfahren zur Herstellung von Alpha-Hydroxyamid und Alpha-Hydroxysäure
DE59200764D1 (de) Verfahren und Einrichtung zur Aufbereitung oder Herstellung von Kunststoffen.
DE68912655D1 (de) Verfahren zur Herstellung von Decabromediphenylalkanen und Decabromdiphenylethan.
ATE111439T1 (de) Verfahren zur herstellung von levodopa.
DE69109427D1 (de) Blockcopolymerdispersionen und Verfahren zur Herstellung von Blockcopolymerdispersionen.
DE59101232D1 (de) Verfahren und Mittel zur Herstellung von Bohrungen.
DE3668765D1 (de) Verfahren zur herstellung von borstenwaren und danach hergestellte borstenwaren.
DE59002322D1 (de) Verfahren zur herstellung von 1,1,1,3,3,3-hexafluorpropan und 2-chlor-1,1,1,3,3,3-hexafluorpropan.
DE69016245D1 (de) Artikel zur Gewebekonditionierung.
DE69014109D1 (de) Verfahren zur bräunung mit mikrowellen und so hergestelltes produkt.
DE69416862D1 (de) Transparente, antistatische, thermoplastische zusammensetzung und verfahren zur herstellung derselben
DE3579630D1 (de) Lichtempfindliches kunststoffzusammensetzung und verfahren zur herstellung von photoschutzlackbildern damit.
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
DE59001713D1 (de) Verfahren und anlage zur herstellung von holzspanplatten und aehnlichen plattenwerkstoffen.
DE69115296D1 (de) Verfahren zur eigenschaftsverbesserung von beschichteten, verstaerkten thermoplastartikeln und damit hergestellte produkte.
DE59101473D1 (de) Verfahren zur Herstellung von N-aryl-substituierten 2-Aminoalkyl-2-hydroxy-alkylaminen und N-arylsubstituierten Piperazinen.
DE59106553D1 (de) Verfahren zur herstellung von chlorfluornitrobenzolen und difluornitrobenzolen.
DE68911148D1 (de) Zusammensetzungen und verfahren zur herstellung von schaumkunststoffen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee